Telaprevir increases cure rate in hepatitis C study

05/26/2010 | New York Times (tiered subscription model), The

Hepatitis C drug telaprevir reduced the virus to an undetectable level in 75% of clinical-trial patients who received the standard dose in combination with interferon and ribavirin, Vertex Pharmaceuticals reported. The study focused on patients with Genotype 1 hepatitis C who had not received treatment before the trial.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ